ProQR Therapeutics N.V. PRQR 深 沪
已收盘 05-22 16:00:00 美东时间
1.56
+0.120
+8.33%
华盛通- 最 高1.575
- 今 开1.45
- 成交量 55.26万股
- 最 低 1.45
- 昨 收 1.44
- 总市值 1.64亿
- 52周最高 3.10
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 1.33
- 委 比 -43.89%
- 总股本 1.05亿
- 历史最高 27.60
- 量 比 0.82
- 振 幅 8.68%
- 历史最低 0.53
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same period last year.
05-12 19:13
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
ProQR Therapeutics N.V. announced its Annual General Meeting (AGM) will take place on June 2, 2026, in Amsterdam. Shareholders can access relevant documents on ProQR’s website or the SEC’s site. The company highlights its Axiomer™ RNA editing technology, which uses ADAR to correct RNA mutations, potentially treating diverse diseases. ProQR focuses on developing transformative RNA therapies for both rare and prevalent conditions.
05-04 12:00
ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI
04-08 20:02
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
ProQR Therapeutics will host a virtual event on April 8, 2026, to discuss its RNA editing pipeline beyond AX-0810, including new programs and clinical data updates. The event will feature presentations and a Q&A session. ProQR's Axiomer™ technology uses ADAR to edit RNA, correcting mutations and potentially treating various diseases. Learn more at www.proqr.com or register at the provided link.
03-25 12:00
ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 10 percent increase over losses of $(0.10) per share from
03-13 06:17
ProQR Announces Year End 2025 Operating and Financial Results
ProQR Therapeutics reported advancements in its RNA editing platform, including Phase 1 dosing for AX-0810, selection of development candidates AX-2402 for Rett syndrome, and AX-2911 for MASH, and achieved $4.5 million in Lilly collaboration milestones in 2025. The company ended 2025 with €92.4 million in cash, supporting operations into mid-2027. AX-0810 target engagement data is expected in early 2026, with plans to expand trials to include PSC...
03-12 11:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Mon...
03-09 20:05
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
ProQR Therapeutics N.V. will present at the Citizens Life Sciences Conference on March 11, 2026, to discuss its Axiomer™ RNA editing technology, a next-generation approach using ADAR to correct RNA mutations, offering potential new treatments for diverse diseases.
03-03 21:30
ProQR Announces Planned Changes to Board Composition
ProQR Therapeutics announced that Dinko Valerio and Alison Lawton will step down from its Board at the 2026 Annual General Meeting as their terms end. The changes reflect the company's growth and commitment to strong governance and succession planning. The Board thanks them for their significant contributions and efforts that have impacted ProQR's development. ProQR is advancing its RNA therapy platform, Axiomer™, which uses the body's ADAR enzym...
02-09 13:00
